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a b s t r a c t 
In addition to their classical antigen presenting functions, MHC class II molecules potentiate the TLR-triggered
production of pro-inﬂammatory cytokines. Here, we have addressed the effect of Tollip and MARCH1 on the
regulation of MHC II trafﬁcking and TLR signaling. Our results show that MARCH1-deﬁcient mice splenocytes
are impaired in their capacity to produce pro-inﬂammatory cytokines in response to poly(I:C) and that TLR3
and MHC II molecules interact in the endocytic pathway. Knocking down Tollip expression in human CIITA +
HeLa cells increased expression of HLA-DR but reduced the proportion of MHC II molecules associated with
the CLIP peptide. Truncation of the HLA-DR cytoplasmic tails abrogated the effect of Tollip on MHC class
II expression. While overexpression of Tollip did not affect HLA-DR levels, it antagonized the function of
co-transfected MARCH1. We found that Tollip strongly reduced MARCH1 protein levels and that the two
molecules appear to compete for binding to MHC II molecules. Altogether, our results demonstrate that
Tollip regulates MHC class II trafﬁcking and that MARCH1 may represent a new Tollip target. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
In humans, 10 members of the toll-like receptor (TLR) family
of proteins recognize different pathogen-associated molecular pat-
terns (PAMPs) through their luminal leucine-rich repeats [ 1 ]. TLRs
are type I trans-membrane proteins capable of forming homo- and
heterodimers [ 2 ]. While their expression patterns often differ, some,
like TLR1, are ubiquitously expressed [ 3 ]. They localize on cell surface
(TLR1, 2, 4, 5, 6 and 11) or in endosomes (TLR3, 7, 8 and 9), in line
with the subcellular accumulation of their speciﬁc ligands [ 4 , 5 ]. TLRs
are essential in the early events of innate immunity as well as in the          
Abbreviations: TLR, toll-like receptor; PAMPs, pathogen-associated molecular pat- 
terns; TIR, Toll / IL-1 receptor; APCs, antigen presenting cells; SOCS1, suppressor of 
cytokine signaling 1; Tollip, Toll-interacting protein; TBD, Tom1-binding domain; CUE, 
coupling of ubiquitin to endoplasmic reticulum degradation domain; C2, internal pro- 
tein kinase C conserved region 2; TGFBR1, TGF-beta type I receptor; IRAK, IL-1 receptor- 
associated kinase; MHC II, MHC class II; DCs, dendritic cells; iDCs, immature DCs; 
MARCH, membrane-associated RING-CH; MIR, modulator of immune recognition; CI- 
ITA, class II trans-activator; Tfr, transferrin receptor; Btk, Bruton tyrosine kinase; IL-1RI, 
IL-1 receptor; IL-1RAcP, IL-1R-associated protein; MFVs, mean ﬂuorescence values. 
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Open access under CC BY-NC-ND licdevelopment of robust adaptive immune responses [ 6 , 7 ]. Microbial
products, such as LPS and DNA, trigger signaling cascades through
the cytoplasmic Toll / IL-1 receptor (TIR) domain and various adap-
tor proteins, which include MyD88, TIRAF, TRIM, TRAF and IRAK [ 7 ].
One exception is TLR3, which is MyD88-independent and thus sig-
nals through TRIF [ 8 ]. The recognition of PAMPs by TLRs ultimately
leads to NF- κB and AP-1 activation and the production of many pro-
inﬂammatory cytokines, such as TNF- α and IL-6 [ 9 ]. Additionally,
type I interferons are induced through the phosphorylation of IRF3
and IRF7 [ 10 ]. Thus, TLRs are important in the early innate immune
responses against pathogens. These initial mediators and the activa-
tion of antigen presenting cells (APCs) will also impact the ensuing
adaptive immunity. 
Many accessory molecules, which modulate the activity of TLRs,
have been identiﬁed. Some are implicated, for instance, in the fold-
ing, trafﬁcking and processing of the TLRs [ 11 ]. Other cofactors in-
clude CD14 and granulin, which have been shown to deliver speciﬁc
ligands to TLR4 and 9 respectively. TLR signals are also regulated by
molecules such as the suppressor of cytokine signaling 1 (SOCS1) and
Toll-interacting protein (Tollip) [ 12 –14 ]. While four isoforms of Tol-
lip have been described in humans and mice, the canonical protein is
composed of three domains [ 15 ] and is ubiquitously expressed [ 14 ]. A
TBD (Tom1-binding domain) and a CUE (coupling of ubiquitin to en-
doplasmic reticulum degradation) domain, located on the N- and C-
terminal regions respectively, confer a potential for multiple protein
interactions [ 16 ]. Finally, a C2 (internal protein kinase C conservedense.
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Megion 2) domain binds phosphoinositides and is responsible for the 
ntracellular trafﬁcking of the protein to the endocytic pathway [ 17 ]. 
While experiments on deﬁcient mice suggested that Tollip was 
eeded for maximal cytokine production in response to low doses 
f TLR agonists, most studies imply a negative regulatory role for 
ollip in various signaling pathways [ 14 , 18 –22 ]. For instance, Tol- 
ip has been shown to participate in IL-1 β signaling as well as in 
he intracellular sorting and degradation of the ubiquitinated IL-1RI 
eceptor [ 14 , 23 ]. Similarly, Tollip was recently shown to modulate 
GF- β signaling through its interaction with Smad7 and by regulat- 
ng the degradation of the activated TGF- β type I receptor (T βRI) 
 20 ]. Also, Tollip associates with TLRs and attenuates signaling by 
uppressing the activity of IL-1 receptor-associated kinase (IRAK) and 
F- κB activation [ 18 , 22 , 24 ]. A high throughput shRNA screen identi- 
ed Tollip as a potential regulator of MHC class II (MHC II) trafﬁcking 
 25 ]. If ubiquitin links MHC II and Tollip pathways remains to be ad- 
ressed. Interestingly, ubiquitination of MHC II molecules can occur 
n many different physiological conditions and cell types, allowing, for 
nstance, maturation-dependent ﬁne-tuning of antigen presentation 
n dendritic cells (DCs) [ 26 , 27 ]. 
Up to now, only two E3 ubiquitin ligases have been shown to 
odify MHC class II molecules. These are the membrane-associated 
ING-CH (MARCH) 1 and 8, two close homologues of viral modulator 
f immune recognition (MIR) proteins [ 28 , 29 ]. MARCH1 is mostly ex- 
ressed in the spleen and more speciﬁcally in follicular B cells [ 30 , 31 ]. 
omparably to the class II trans-activator (CIITA), which is the mas- 
er regulator of MHC II gene transcription, MARCH1 appears to be 
he master regulator of MHC II expression at the post-translational 
evel [ 32 ]. Indeed, the increased MHC II surface expression follow- 
ng activation of immature DCs (iDCs) is accompanied by the down- 
egulation of MARCH1 expression [ 33 , 34 ]. On the other hand, the 
mmunosuppressive cytokine IL-10 up-regulates MARCH1 in mono- 
ytes and DCs to decrease MHC II expression and antigen presenta- 
ion [ 35 , 36 ]. MARCH1 also ubiquitinates the transferrin receptor (Tfr), 
D86, HLA-DM and Fas to modulate their expression and antigen pre- 
entation [ 30 , 31 , 37 –39 ]. 
The impact of MARCH1 on the trafﬁcking of MHC II has conse- 
uences beyond antigen presentation. It has been shown recently 
hat DCs from MARCH1-deﬁcient mice are impaired in the produc- 
ion of the pro-inﬂammatory cytokines IL-12 and TNF- α in response to 
PS, suggesting that this ubiquitin ligase might be another accessory 
olecule involved in TLR signalling [ 40 ]. This activity of MARCH1 is 
ependent on the ubiquitination of MHC II molecules since the same 
henotype was observed in MARCH1-proﬁcient mice expressing non- 
biquitinable I-A b β chain [ 40 ]. The fact that MHC II molecules poten- 
iate LPS-induced signaling in human monocytes and mouse cells has 
een known for many years [ 41 ]. It was postulated that a LPS-binding 
eceptor may interact with MHC II molecules to up-regulate TNF α
ecretion. Then, using MHC II-deﬁcient primary cells from human pa- 
ients or knock-out mice as well as reconstituted in vitro systems, 
auener and collaborators showed that MHC II molecules enhance 
LR-induced responses [ 42 , 43 ]. More recently, it has been shown that 
HC class II molecules promote TLR signaling in antigen presenting 
ells by maintaining activation of the Bruton tyrosine kinase (Btk) 
 44 ]. 
The cooperation between MHC II and TLRs promotes the innate as 
ell as the adaptive immune response. Direct interactions between 
he MHC II and the TLRs have been observed and the generation 
f peptide-MHC class II complexes depends on endosomal trafﬁck- 
ng of LPS-associated antigens in a phagosome-autonomous fashion 
 43 , 45 , 46 ]. Considering these clear functional links between innate 
nd adaptive immunity and the interplay between the TLR4 signal- 
ng and the antigen presentation pathway, we hypothesized, as pro- 
osed recently, that Tollip might regulate the trafﬁcking of MHC II 
olecules [ 47 ]. Our results demonstrate a direct interaction between 
HC II and Tollip, which is reduced in the presence of MARCH1. Also, Tollip impairs the expression of MHC II and of MARCH1, in line with 
its previously described inhibitory functions. 
2. Materials and methods 
2.1. Antibodies 
L243 (HLA-DR), XD5.117 (HLA-DR β), CerCLIP.1 (CLIP / HLA-DR 
complexes), BU45 (human invariant chain), MaP.DM1 (HLA-DM) 
mAbs have been previously described [ 48 –50 ]. The rabbit antisera 
against denatured HLA-DR α and HLA-DR β were a kind gift from 
Dr. Raﬁck S ´ekaly (Vaccine and Gene Therapy Institute, Port St-Lucie, 
FL, USA). Rabbit polyclonal anti-GFP that recognizes both GFP and 
YFP, Alexa 488 - and Alexa 633 -ﬂuor-coupled goat-anti mouse antibod- 
ies were purchased from Invitrogen (Laval, QC, Canada). The mouse 
anti-ﬂag antibody was bought from Sigma (St-Louis, MS, USA). The 
rabbit anti-human Tollip was purchased from the cell signaling tech- 
nology (Pickering, ON, Canada). The mouse anti-human Tfr OKT9 an- 
tibody was bought from ebioscience (San Diego, CA, USA). The mouse 
anti-MARCH1 (H1) was described previously [ 33 ]. The mouse anti- 
actin antibody was purchased from Millipore (Billerica, MA, USA). 
2.2. Reagents 
Poly(I:C) (Invivogen, San Diego, CA, USA) was used at a ﬁnal con- 
centration of 2 μg / mL. LPS was purchased from Sigma (St-Louis, MS, 
USA) and used at a concentration of 100 ng / mL. Benzyl Coelenter- 
azine and luciferine were used at ﬁnal concentrations of 5 uM and 
20 μg / mL, respectively (Nanolight technology, Pinetop, AZ, USA). 
2.3. Cell lines and mice 
HeLa DR1, HeLa DR1 TM / TM, HeLa CIITA, HeLa CIITA / DO and HEK 
293E CIITA stable transfectants were described previously [ 51 , 52 ]. 
Cells were cultured in DMEM supplemented with 5% FBS (Wisent, 
Saint-Jean-Baptiste, QC, Canada). 
C57BL / 6 (B6) mice were purchased from Charles River Laboratory 
(Wilmington, MA, USA). The M1K-O mice were described previously 
[ 31 ]. Xid mice were purchased from The Jackson Laboratory (Bar Har- 
bor, ME, USA). Use of animals as described herein was approved by the 
University of Montreal’s Institutional Animal Care and Use Committee 
(CDEA; protocol #12–042). 
2.4. Plasmids and constructs 
The ﬂag, Rluc, EGFP 2 or EYFP tags were fused by PCR overlap to the 
N-terminus of HLA-DR βor TLR3 molecules using pcDNA3.1 ﬂag MCS, 
pcDNA3.1 Rluc MCS, pcDNA3.1 EYFP MCS or pcDNA3.1 EGFP 2 MCS 
constructs. The cDNAs for the DR αTM and DR βTM chains include 
a stop codon immediately after the transmembrane coding regions, 
as described previously [ 53 , 54 ]. The GFP-SOCS1 and the GFP-Tollip 
constructs were obtained from Dr. Gerardo Ferbeyre (Universit ´e de 
Montr ´eal, Montreal, QC, Canada) and Dr. Liwu Li (Virginia Polytech- 
nic Institute and State University, Virginia, USA) respectively. The 
pcDNA3.1 MARCH1, pcDNA3.1 EYFP-MARCH1 and pcDNA-3.1 EYFP- 
MARCH1K-0 were described previously [ 48 ]. For the luciferase assay, 
we used the P2(2x)TK-pGL3 NF- κB reporter plasmid that was de- 
scribe previously [ 55 ]. 
2.5. Transfections 
For HeLa, 1 ×10 6 cells were plated 24 h prior to transfection in 
10 cm petri dishes and transfected using lipofectamine LTX and Plus 
reagents according to the manufacturer’s protocol (Invitrogen, Laval, 
QC, Canada). For HEK 293T and HEK 293E CIITA, 1.5 ×10 6 cells were 
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Fig. 1. The response to poly(I:C) and LPS is impaired in the Ii KO and M1 KO mice. (A) 
Splenocytes from C57BL / 6, Ii KO and Xid mice were isolated and treated ex vivo for 
24 h with LPS prior to RNA extraction and qPCR analysis of TNF α mRNA expression. 
(B) Splenocytes from C57BL / 6, Ii KO and M1 KO mice were isolated and treated ex 
vivo for 24 h with either LPS or poly(I:C) prior to RNA extraction and qPCR analysis of 
TNF α mRNA expression. Expression is illustrated as fold level compared to the value 
of untreated C57BL / 6 cells, which was set at 1. Data is representative of at least two 
different experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 plated and transfected 24 h later using 3 μg of polyethyleimine per
μg of DNA (Polyscience, Warrington, PA, USA). 
2.6. Flow cytometry 
Cells were harvested, ﬁxed, permeabilized using saponin and incu-
bated with primary antibodies. After 45 min at 4 ◦C, cells were washed
twice in PBS and incubated for another 45 min with the secondary an-
tibody in PBS. Cells were analyzed on a FACS 
®
calibur (Becton Dick-
inson, CA). 
2.7. Immunoprecipitation and western-blot analysis 
Cells were lysed on ice in 1% Triton X-100 lysis buffer supple-
mented with a complete protease inhibitor cocktail (Roche, Laval,
QC) and centrifuged. The post-nuclear supernatants were pre-cleared
for 1 h with protein G-coated sepharose beads (GE Healthcare, Mis-
sissauga, ON, Canada) and speciﬁc proteins were immunoprecipi-
tated overnight using protein G-sepharose beads pre-coated with the
selected antibody. The beads were washed and the samples were
solubilized in reducing sample buffer, boiled and analyzed by im-
munoblotting following separation of proteins on 12% acrylamide
gels, as described. Proteins were transferred to Hybond ECL mem-
brane (GE Healthcare, Mississauga, ON, Canada) and analyzed with
speciﬁc mAbs. Goat anti-mouse and anti-rabbit antibodies coupled
to peroxydase (Bio / Can Scientiﬁc) were used as secondary antibod-
ies and detected by chemiluminescence (BM Chemiluminescence
Blotting Substrate (POD), Roche, Laval, QC, Canada). The ﬁlms were
scanned and analysed using Photoshop CS4 for signal quantiﬁcation.
Brieﬂy, the colors were inverted and the mean intensity of the signal
in a blank area was subtracted from that of different portions of the
same size. 
2.8. Bioluminescence resonance energy transfer (BRET) experiment 
The pcDNA3.1 DR β Rluc (20 ng) and pcDNA3.1 DR α (20ng)
were co-transfected in 1.25 ×10 5 HEK 293T cells with 0–
500 ng of pcDNA3.1 TLR3-EYFP, resulting in different ﬂuorescence /
luminescence ratios [ 56 ]. Cells were harvested after 48 h and washed.
For each sample, 1 ×10 5 cells were plated in duplicate into a 96-well
plate. The background values of ﬂuorescence were determined on a
Mithras LB940 spectroﬂuorometer before the addition of coelenter-
azine by measuring the ﬂuorescence emission at 538 nm after an exci-
tation at 485 nm. After the addition of coelenterazine at a ﬁnal concen-
tration of 5 μM, the luminescence and ﬂuorescence emissions in the
460–500 nm and 510–550 nm windows, respectively, were measured
on a Mithras LB940 multidetector plate reader. The BRET ratio on the
y -axis was calculated by dividing the acceptor-emitted ﬂuorescence
by the donor-emitted luminescence. BRET ratios were normalized
by subtracting the background signal from cells transfected without
YFP. The ﬂuorescence over luminescence ratio on the x -axis is the
ratio between the ﬂuorescence of acceptor (YFP–YFP0, where YFP0 is
the ﬂuorescence value of cells expressing the BRET donor alone) and
the luminescence of the acceptor. 
2.9. Microscopy 
For ﬂuorescence resonance energy transfer (FRET) experiments,
HeLa cells were used as they are highly adherent. Cells (6.25 ×10 4 per
well) were plated on 35 mm glass bottom microwell dishes (MatTek
Cultureware, Ashland, MA, USA) 24 h prior to transfection. Cells were
transfected as described above and incubated for 48 h. Images of live
cells were taken using a LSM 510 Meta Zeiss confocal microscope. 2.10. Luciferase assay 
Cells were transfected with the NF- κB luciferase reporter plasmid
and stimulated for 5 h with various amounts of poly(I:C). After stim-
ulation, cells were washed and incubated with luciferine for 5 min
prior to luminescence reading using a luminescence counter (Perkin–
Elmer, Vaudreuil-Dorion, QC, Canada). 
2.11. siRNA 
Tollip speciﬁc and non-targeting control siRNAs were purchased
from QIAGEN (Toronto, ON, Canada). The siRNAs were transfected
using HiPerfect reagent according to the manufacturer’s recommen-
dations (QUIAGEN, Toronto, ON, Canada). 
2.12. Real-time quantitative PCR 
RNA / DNA were extracted using TRIzol (Sigma, St. Louis, MO, USA),
DNA digestion (Ambion, Grand Island, NY, USA) and reverse transcrip-
tion of RNA (Invitrogen, Laval, QC, Canada) were all performed as per
the manufacturers ’ instructions. Each sample was run in duplicates
and a no-template control without cDNA was run for every primer
set. Primer sequences are available upon request. 
3. Results 
3.1. Accessory molecules improve TLR signaling 
Recent evidence suggest that MHC II molecules are pivotal in the
innate immune response initiated by the TLRs [ 43 ]. Liu et al. have
demonstrated that a multi-protein complex composed of TLR4, CD40,
MHC II molecules and Btk is responsible for transducing signals from
TLR4 [ 44 , 57 ]. Interestingly, it appears that the complex forms in the
endocytic pathway and originates from the intracellular pool of MHC
II. To further support the role of MHC II in the TLR signaling complex
and the importance of MHC II trafﬁcking to endosomes, we tested the
cellular response to LPS in Ii-deﬁcient mice. This chaperone associates
with MHC II in the ER and its cytosolic di-leucine signals direct newly
synthesized complexes to endosomes [ 58 ]. We used whole spleno-
cytes since the majority of MHC II + cells are B lymphocytes, which
respond to LPS [ 59 ]. Our results show that Ii-deﬁciency reduced the
TNF- α mRNA up-regulation in splenocytes in response to LPS ( Fig.
1 A). As a control, we also tested Xid mice, which have a mutation in
the Btk gene [ 60 ]. Btk KO mice have been shown very recently to be
impaired in their TLR response but expression proﬁling of the Xid and
the Btk KO mice demonstrated important differences, suggesting that
their phenotypes are not entirely redundant [ 44 , 61 ]. Results in Fig.
1 A conﬁrmed the role of Btk in TLR4 signaling as TNF- α production
was lower in LPS-treated splenocytes from Xid mice. 
20 Marie-Claude Bourgeois-Daigneault et al. / Results in Immunology 3 (2013) 17–25 
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cMature MHC II molecules at the plasma membrane get ubiquiti- 
ated by MARCH1 and are sent to late compartments [ 28 , 29 ]. Pro- 
nﬂammatory cytokine production was found to be impaired in DCs 
rom MARCH1-deﬁcient mice and this phenotype was caused by the 
ack of I-A b ubiquitination [ 40 ]. As MARCH1 is strongly expressed in 
 cells [ 31 , 62 ], we tested splenocytes from MARCH1-proﬁcient and 
deﬁcient animals for the up-regulation of the TNF- αgene expression 
n response to LPS. Also, we extended these experiments to the study 
f poly(I:C) as MHC II deﬁciency also down-regulated TLR3 signaling 
 44 ]. Our results demonstrate that mouse cells deﬁcient for either Ii or 
ARCH1 accessory molecules are impaired in their capacity to pro- 
uce TNF- α in response to TLR3 or TLR4 ligands ( Fig. 1 B). These datas 
re in line with a generalized functional role in APCs of intracellular 
HC II molecules and Btk for TLR signaling. 
.2. MHC II molecules interact with TLR3 
The above-described results are in line with a role of MHC II 
olecules in the regulation of innate signals, including TLR3 ligands. 
LR3 is the prototypical example of the TLR family members that 
eside in intracellular compartments [ 5 ]. Thus, we assessed by co- 
mmunoprecipitation the capacity of TLR3 and human MHC II to as- 
ociate. HEK 293E CIITA cells were co-transfected with a ﬂag-tagged 
LR3, lyzed and immunoprecipitated with a ﬂag-speciﬁc mAb. Fig. 2 A 
hows a co-precipitated HLA-DR α band on immunoblots (left panel). 
he interaction was speciﬁc as the control HLA-DM did not bind TLR3 
n the same conditions ( Fig. 2 A, right panel). A similar type of experi- 
ent using transfected HEK 293 cells previously unveiled TLR2–HLA- 
R interactions [ 43 ]. 
The interaction between MHC II molecules and TLR3 was con- 
rmed by BRET. This technique offers great sensitivity and allows the 
onitoring of interactions in living cells, thereby avoiding possible 
rtifacts resulting from cell lysis during co-immunoprecipitation ex- 
eriments [ 56 ]. TLR3 was linked to EYFP, and co-transfected in HEK 
93T cells along with an Rluc-fused HLA-DR molecule. After 48 h, lu- 
inescence and ﬂuorescence emissions were measured. The BRET 
atio reached a plateau, indicating a speciﬁc interaction rather than 
tochastic collisions between the two molecules ( Fig. 2 B). 
To get insights into the localization of the HLA-DR–TLR3 complex, 
e performed a FRET experiment between EGFP 2 –HLA-DR and TLR3- 
YFP ( Fig. 2 C). This technique allows to co-localize the signals of the 
wo interacting partners in living cells and to visualize the energy 
ransfer by the detection of YFP ﬂuorescence emission following the 
xcitation of the EGFP 2 (FRET signal). FRET was detected in intracellu- 
ar vesicles and the interaction was conﬁrmed with the release of the 
GFP 2 signal after bleaching a distinct area ( Fig. 2 C, bottom panels). 
he relative ﬂuorescence intensities of HLA-DR and TLR3 in the des- 
gnated area (white square) were plotted as bar chart ( Fig. 2 C, right 
anels). 
The fact that HLA-DR interacts with TLR3 suggests that MHC II 
olecules may also modulate the response to poly(I:C) in human 
ells. To test this hypothesis, we measured the activity of a reporter lu- 
iferase whose transcription is under the control of NF- κB-responsive 
romoter elements. Cells were transfected with the reporter con- 
truct together with combinations of HLA-DR and TLR3 before treat- 
ent with poly(I:C) for 5 h. Fig. 2 D shows that co-expression of HLA- 
R is needed for poly(I:C) to trigger TLR3 signaling in these conditions. 
ltogether, these results demonstrate the synergistic effect of MHC II 
olecules on the TLR3 response. 
.3. Tollip regulates MHC II trafﬁcking 
Very recently, using the human MelJuso cell line, a shRNA-based 
igh throughput screen suggested a role for Tollip in the trafﬁcking 
f MHC II molecules [ 25 ]. We further investigated this issue in HeLa 
ells stably transfected with CIITA and HLA-DO (HeLa-CIITA-DO). We used these cells because the overexpressed HLA-DO increases the 
amount of CLIP, which is otherwise almost undetectable in HeLa CI- 
ITA cells [ 51 , 52 ]. Also, the absence of endogenous MARCH1 in HeLa 
cells allowed us to uncouple the effect of Tollip and MARCH1. HeLa- 
CIITA-DO cells were treated with control or speciﬁc siRNAs and the 
efﬁcient knockdown of Tollip mRNA expression was demonstrated by 
qPCR ( Fig. 3 A). Flow cytometry experiments demonstrated that the 
transfection of Tollip-speciﬁc siRNAs resulted in a 29% increase in the 
mean ﬂuorescence value (MFV) for MHC II expression at the plasma 
membrane ( Fig. 3 B left and right panels). This increase does not ap- 
pear to result from relocalization of some intracellular pools. Indeed, 
the total amount of MHC II molecules, as measured from the staining 
of permeabilized cells, was also increased ( Fig. 3 B, middle and right 
panels). These results suggest that Tollip decreases the turn-over of 
MHC II molecules. Interestingly, we found that knocking down Tol- 
lip reduced the amount of CLIP / MHC II complexes but increased the 
levels of unprocessed Ii ( Fig. 3 C). We performed the same experi- 
ments in HeLa CIITA cells and reached similar conclusions, showing 
that these results are independent of HLA-DO overexpression (data 
not shown). The impact of Tollip knockdown on CLIP and Ii suggests 
a somewhat slower trafﬁcking of immature MHC II / Ii complexes to 
late endosomes. Altogether, these results conﬁrm that Tollip plays a 
direct or indirect role in the maturation of MHC II / Ii complexes as 
well as in the degradation of MHC II molecules [ 25 ]. 
To get insights into the mechanism of action of Tollip, we knocked 
down its expression in cells transfected exclusively with HLA-DR. 
Again, Tollip-speciﬁc siRNAs increased the plasma membrane ex- 
pression of HLA-DR by 24% ( Fig. 3 D, left and right panels). This re- 
sult demonstrated that the effect of Tollip on MHC II molecules is not 
dependent on the presence of Ii. We repeated this experiment using 
a HLA-DR1 molecule devoid of its α and β chains cytoplasmic re- 
gions (DR1 TMTM). Interestingly, there was no increase in the level of 
the truncated HLA-DR ( Fig. 3 D, middle and right panels). Altogether, 
these results conﬁrm the role of Tollip on MHC class II trafﬁcking and 
demonstrate that the cytoplasmic tails of MHC II are required for this 
effect. 
3.4. Overexpressed Tollip interferes with MARCH1 activity 
Tollip, through its ubiquitin-interacting CUE domain, is neces- 
sary for sorting of the activated IL-1 receptor (IL-1RI) at late en- 
dosomes [ 23 ]. Interestingly, MARCH8 was recently found to ubiq- 
uitinate and down-regulate the IL-1R-associated protein (IL-1RAcP), 
which is needed to form the membrane proximal signalosome [ 63 ]. 
The fact that the MHC II cytoplasmic tails were needed for Tollip to 
exert its effect suggested that ubiquitination-related events may be 
involved. This could explain the rather marginal effect of Tollip knock- 
down on MHC II expression in Hela cells as in the absence of over- 
expressed MARCH1 or MARCH8, ubiquitination of MHC II molecules 
is limited [ 31 ]. Thus, we postulated that overexpressing both Tollip 
and MARCH1 might have dramatic consequences and precipitate the 
degradation of MHC II molecules. To test this hypothesis, Tollip and 
MARCH1 were transiently transfected separately or together in HEK 
293E CIITA cells. First, transfection of GFP-Tollip alone did not affect 
the surface expression of two of its targets, MHC II and Tfr ( Fig. 4 A, 
left and right panels). No difference was observed in the expression 
of HLA-DR or Tfr between the non-transfected cell population and 
the Tollip-expressing cells showing green ﬂuorescence. This suggests 
that the basal endogenous levels of Tollip are sufﬁcient to exert its ef- 
fect on MHC II. On the other hand, cells co-transfected with MARCH1 
and YFP as a tracer showed the well-characterized MHC II and Tfr 
down-regulation in ﬂuorescent cells. Interestingly, to our surprise, 
co-expression of Tollip antagonized the effect of MARCH1 and re- 
duced the magnitude of the MHC II and Tfr down-regulation ( Fig. 
4 A, right panels). The mean ﬂuorescence values (MFVs) obtained for 
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Fig. 2. HLA-DR interacts with TLR3 in live cells. (A) HEK 293E CIITA cells were transfected with TLR3-ﬂag. 48 h post-transfection, cells were lysed and immunoprecipitated with a 
ﬂag speciﬁc antibody and blotted for HLA-DR α or HLA-DM β. Asterisks represent the antibodies. (B) HEK 293T cells were transfected with HLA-DR–Rluc and increasing amounts 
of TLR3-EYFP. The BRET ratio was calculated by dividing the ﬂuorescence with substrate, subtracted from the ﬂuorescence without substrate, by the luminescence. Error bars 
represent standard deviation obtained for two different transfections. (C) FRET experiment performed in HeLa cells 48 h after transfection with TLR3-EYFP and HLA-DR α–EGFP 2 / β. 
One stack of living cells was observed by confocal microscopy. The dotted square shows the bleached area. The signal intensity for the bleached region was quantiﬁed for pre- and 
post-bleach. The signals were normalized for the ones of the corresponding regions prior to the beach and plotted in a bar chart. (D) Luciferase assay of HeLa or HeLa HLA-DR1 
cells transfected or not with TLR3 and the NF- κB-luciferase reporter plasmid. The cells were stimulated for 5 h with poly(I:C) prior to the addition of luciferine. Error bars represent 
standard deviation obtained for two different transfections. Data is representative of a least three different experiments. 
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Fig. 3. Tollip knockdown increases HLA-DR expression. (A) HeLa-CIITA-DO cells were 
transfected with control or TOLLIP-speciﬁc siRNAs, and cultured for 48 h at 37 ◦C. The 
bar chart represents the mRNA expression of Tollip for cells transfected with speciﬁc 
or control siRNA. (B) The cells were stained and analyzed by ﬂow cytometry for cell 
surface and total expression of HLA-DR (L243 Ab). The mean ﬂuorescence values (MFV) 
were plotted to account for variations in the levels of HLA-DR. Error bars represent 
standard deviation obtained for two different transfections. (C) Cells were stained for 
cell surface expression of CLIP (CerCLIP) and total expression of invariant chain (BU45). 
The mean ﬂuorescence values (MFV) were plotted to account for variations in the levels 
of CLIP and invariant chain Error bars represent standard deviation obtained for two 
different transfections. (D)HeLa-DR1 and HeLa-DR1 TM / TMcells were transfected with 
control or Tollip-speciﬁc siRNAs, and cultured for 48 h in 37 ◦C. Cells were stained for 
cell surface expression of HLA-DR (L243 Ab). The mean ﬂuorescence values (MFV) were 
plotted to account for variations in the levels of HLA-DR expression. Error bars represent 
standard deviation obtained for two different transfections. Data is representative of 
at least two different experiments. 
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Fig. 4. Tollip blocks MARCH1-mediated down-regulation of HLA-DR. (A) HEK 293E 
CIITA cells were transfected with GFP-Tollip, EYFP and MARCH1 or GFP-Tollip and 
MARCH1. Cells were stained for cell surface expression of HLA-DR and Tfr. Bar charts 
represent the mean ﬂuorescence intensity of EYFP or GFP positive cells. (B) HeLa CIITA 
cells were transfected with GFP-Tollip, EYFP and MARCH1 or GFP-Tollip and MARCH1. 
Cells were stained for cell surface expression of HLA-DR. The bar chart represents the 
mean ﬂuorescence intensity of EYFP or GFP positive cells. (C) Cells were lysed and 
blotted for HLA-DR α and HLA-DR β. The intensity of the bands was quantiﬁed and 
divided by the one of cells transfected with the YFP control. Results are represented as 
a bar chart. Data is representative of at least two different experiments. LA-DR and Tfr expression in the transfected populations were plot- 
ed in the right panels. To generalize the ﬁndings on MHC II molecules, 
hese experiments were repeated in HeLa CIITA cells and similar re- 
ults were obtained ( Fig. 4 B). Moreover, analysis of total cell lysates 
n immunoblots demonstrated that Tollip protects MHC II molecules 
rom the MARCH1-induced degradation ( Fig. 4 C). Altogether, these 
esults indicate that overexpression of Tollip antagonizes the activity 
f MARCH1 and suggest that both molecules compete for binding to 
he cytoplasmic tail of their targets. 
.5. The expression of MARCH1 is reduced in the presence of Tollip 
To get insights into the functional basis of MARCH1 dysfunction 
n the presence of overexpressed Tollip, we analyzed cell lysates on 
mmunoblots. Fig. 5 A shows that MARCH1 protein levels are greatly 
educed in HeLa and HEK 293E cells co-transfected with Tollip. Actin 
as used as an internal control to conﬁrm equal loading (asterisk). 
n the other hand, Tollip expression was not affected by the co- 
ransfected MARCH1 ( Fig. 5 B). These results demonstrate that, at least 
n part, Tollip restores MHC II surface levels by reducing MARCH1 
xpression. 
Tollip has been shown to regulate the trafﬁcking of the ubiqui- 
inated IL-1RI following activation [ 23 ]. We investigated the impor- 
ance of ubiquitin in the regulation of MARCH1 by Tollip. Our results 
ave demonstrated that MARCH1 is capable of auto-ubiquitination and that mutation of N- and C-terminal lysine residues (M1K0) re- 
duces the overall level of ubiquitination without affecting function- 
ality [ 48 ]. We compared the effect of overexpressed Tollip on the 
activity of M1K0 versus MARCH1 in HEK 293E CIITA cells. Cells were 
transfected with M1K0 or MARCH1 and either GFP-Tollip or an ir- 
relevant GFP-tagged negative control protein (GFP-SOCS1) and the 
cell surface expression of HLA-DR was measured. Fig. 5 C shows that 
Tollip restored MHC II levels in the presence of M1K0 as well, suggest- 
ing that the control of MARCH1 expression is independent of lysine 
ubiquitination in the N- and C-terminal regions of MARCH1. 
3.6. Tollip interacts with HLA-DR 
Despite the clear interplay described above between Tollip and 
MARCH1, we have not been able to co-immunoprecipitate the two 
molecules from transfected cells (data not shown). However, given 
the impact of Tollip siRNAs on the trafﬁcking of HLA-DR ( Fig. 3 ), we 
investigated the possible interaction between the two molecules. HEK 
293E cells were co-transfected with Tollip and / or MARCH1 and HLA- 
DR was immunoprecipitated. Again, we found that Tollip restored the 
overall levels of the HLA-DR αchain ( Fig. 6 A). Interestingly, while HLA- 
DR co-immunoprecipitated GFP-Tollip, this interaction was abrogated 
upon co-expression of MARCH1 ( Fig. 6 B). The endogenous Tollip was 
not detected in these conditions, probably due to the weak expression 
of the protein. These results suggest that MARCH1 and Tollip compete 
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Fig. 5. Tollip reduces the expression of MARCH1. (A) HeLa CIITA and HEK 293E CIITA 
cells were transfected with EYFP-MARCH1, GFP-Tollip or an empty vector (mock). 
Cell lysates were blotted for actin (asterisk) and MARCH1. The intensity of the bands 
was quantiﬁed, normalized to actin and divided by the one of cells transfected with 
MARCH1. Results are represented as a bar chart. (B) HeLa CIITA cells were transfected 
with EYFP-MARCH1, GFP-Tollip or an empty vector (mock). Cell lysates were blotted 
for Tollip. The intensity of the bands was quantiﬁed and the value obtained for cells 
expressing Tollip alone was set to 1. Results are represented as a bar chart. (C) HeLa 
CIITA or HEK 293E CIITA cells were transfected with EYFP-MARCH1 (left panel) of EYFP- 
MARCH1K-0 (right panel) with or without GFP-Tollip, GFP-SOCS1 and EYFP. Cells were 
stained for cell surface MHC II and analysed by ﬂow cytometry. The mean ﬂuorescence 
values for MHC II in cells expressing Tollip and EYFP was set to 1. Data is representative 
of a least two different experiments. 
Fig. 6. Tollip interacts with MHC II. HeLa cells were transfected with MARCH1 and / or 
GFP-Tollip and / or empty vector. Samples were immunoprecipitated with a HLA-DR- 
speciﬁc antibody and blotted for (A) Tollip and (B) DR α. The asterisk indicates the 
position of the immunoprecipitating mouse antibody light chain recognized by the 
goat secondary antibody. Data is representative of at least two different experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 for the binding to HLA-DR. 4. Discussion 
There are many different mechanisms that link the innate and
adaptive arms of the immune response. The ﬁrst phase of innate im-
munity signals danger to the beleaguered organism, setting the stage
and potentiating the following, more speciﬁc, adaptive response. In-
deed, signaling through the TLRs will up-regulate the expression of
MHC II molecules in APCs and trigger important changes in the en-
docytic pathway [ 64 ]. Interestingly, this potentiation can work both
ways. For instance, in professional APCs, the expression of MHC II
molecules ampliﬁes the innate immune response and increases the
production of pro-inﬂammatory cytokines [ 42 ]. As such, the syner-
gistic effect of IFN- γ on the LPS response is, at least in part, mediated
by the up-regulation of MHC II molecules [ 41 ]. Moreover, both innate
and adaptive responses can also synergize, with excessive physiolog-
ical consequences, and lead to autoimmunity [ 65 , 66 ]. These ﬁndings
warrant the reevaluation of the role of accessory proteins on not only
their classical pathway, but on both arms of immunity. 
As such, we looked at the role of the invariant chain on TLR signal-
ing. Our results showing that Ii-deﬁciency impairs TLR responses are
in line with a functional role of MHC II molecules in innate immunity.
More speciﬁcally, given the well-described endosomal sorting signals
of Ii, this data supports the assertion that the intracellular pool of MHC
II molecules is needed for efﬁcient LPS response [ 44 ]. However, we
cannot rule out that the effect of Ii may be due to the lower trafﬁcking
of MHC II molecules from the ER in the C57BL / 6 background [ 67 ].
It will be extremely interesting to test the impact of Ii deﬁciency on
other mice backgrounds where surface MHC II, at least quantitatively,
appears normal [ 67 ]. 
Additionally, we also tested the effect of MARCH1-deﬁciency
on TLR signaling, as this ubiquitin ligase redirects mature MHC II
molecules to late endosomes. Our results conﬁrm and extend those of
Ohmura-Hoshino et al . showing that MARCH1-deﬁcient DCs produce
less TNF- α in response to LPS [ 40 ]. Again, it appears that the presence
of MHC II molecules in the endocytic pathway enhances innate re-
sponses. The exact nature of the compartments involved remains to
be determined. Under the inﬂuence of MARCH1, ubiquitinated MHC II
molecules are sent to late endosomes / lysosomes to be degraded [ 31 ].
Our results also conﬁrmed the interaction between TLRs and MHC II
molecules in the endocytic pathway. It remains to be addressed if a
fraction of the molecules ﬁnd themselves in more specialized vesi-
cles, possibly on their way to lysosomes, to potentially increase the
formation of the CD40 / Btk / MHC II signaling complex [ 44 ]. Both Ii
and MARCH1 are expressed in hematopoietic cells such as immature
DCs and non-activated B cells. Thus, these resting APCs are equipped
to maximally respond to TLR ligands. Our results suggest that both
immature and mature MHC II molecules contribute to TLR signaling.
Therefore, at least two different mechanisms are involved since Ii /
MHC II complexes are not ubiquitinated, at least by MARCH proteins
[ 27 ]. 
The implication of ubiquitination prompted us to investigate a
possible role for Tollip in the regulation of MHC II transport. Our re-
sults demonstrated that Tollip decreased the total protein level of
HLA-DR and the need for the MHC II cytoplasmic tails is certainly
in line with a role of ubiquitination. Interestingly, even though the
ubiquitinated cytoplasmic lysine is conserved, it was postulated that
MHC II polymorphisms may affect TLR signaling [ 41 ]. Future stud-
ies should investigate this important issue and test the capacity of a
panel of alleles and isotypes to associate with various TLRs. Our re-
sults showed that DR and Tollip could interact. Considering that Tollip
is cytoplasmic, this interaction most likely requires the cytoplasmic
tails of MHC II molecules. This is in line with the fact that MARCH1
ubiquitinates the cytoplasmic tails of HLA-DR [ 68 ] and that its ex-
pression reduced the number of Tollip / HLA-DR complexes ( Fig. 6 ).
Conﬁrmation of these molecular interactions in primary mouse and /
or human cells will be needed. However, such experiments will still
24 Marie-Claude Bourgeois-Daigneault et al. / Results in Immunology 3 (2013) 17–25 
r
i
l
a
c
r
c
a
I
e
t
M
T
d
d
u
a
I
t
[
i
a
T
s
t
s
w
h
i
t
c
t
A
t
a
G
t
R
R
A
#
Rely on overexpression assays as the endogenous MARCH1 protein 
s barely detectable [ 69 , 48 ]. In this context, easily transfectable cells 
ines such as CIITA + HeLa or HEK 293 represent suitable alternatives 
s they express endogenous Tollip and have been used in the past to 
haracterize the MHC II pathway (see for example [ 70 , 71 ]). 
The interplay between MARCH1 and Tollip on MHC II molecules is 
eminiscent of the recently described regulation of the IL-1 β receptor 
omplex in stimulated cells. Indeed, both Tollip and MARCH8 bind the 
ccessory IL1RAcP protein and negatively regulate signalling [ 14 , 63 ]. 
t is not known if Tollip down-regulates MARCH8. Interestingly, the 
xpression of Tollip increases in cells treated with LPS, possibly con- 
ributing to the loss of MARCH1 as part of a regulatory loop [ 24 ]. As 
ARCH1 and Tollip do not appear to physically interact, the effect of 
ollip may be indirect and achieved through modulation of the en- 
ocytic pathway. Future studies will address the possible accelerated 
egradation of MARCH1 proteins in the presence of Tollip and the 
nderlying molecular mechanisms. 
That MARCH1 has a positive effect on TLR signalling is in line with 
 recent study indicating that MARCH5 affects the TLR7 response. 
ts mechanism of action would implicate the negative regulation of 
he TLR-inhibitor TANK and the localisation of the E3 in mitochondria 
 72 ]. However, MARCH8 has been shown to impair the TLR4-mediated 
nduction of IL-6 and TNF- α in bone-marrow-derived macrophages 
nd DCs [ 28 , 29 ]. Thus different MARCHs may play opposite effects on 
LR signaling and further studies are required to support our initial 
uggestion for a role of MARCH1 in regulating TLR / MHC II interac- 
ions. The role of Tollip is also controversial as studies in mice have 
uggested that it may potentiate cytokine production in cells treated 
ith low doses of LPS [ 19 ]. Our preliminary observations presented 
ere of an interplay between MARCH1 and Tollip warrant a more 
n-depth mechanistic characterization of the molecular interactions 
aking place between TLRs, MHC II, Tollip, MARCH1 and the endo- 
ytic machinery. Also, future studies should address more in depth 
he effect of Tollip on MHC II trafﬁcking in the absence of MARCH1. 
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